Physician profile
Marcus Hanfling
NPI 1922015007
$3,861.36
in general payments reported to CMS, 2019-2025
26 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $454 · 2021: $664 · 2022: $855 · 2023: $668 · 2024: $338 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,178.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $558.60 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $333.38 | 2020-2024 | Farxiga |
| Abbott Laboratories | $327.07 | 2019-2024 | Cardiomems, Aveir |
| Amgen INC. | $227.67 | 2020-2025 | Repatha |
| Amarin Pharma, INC. | $183.81 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $175.65 | 2019-2023 | Xarelto |
| Cvrx, INC. | $162.80 | 2023-2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.46 | 2021-2025 | Jardiance |
| Pfizer INC. | $126.50 | 2019-2025 | |
| Astellas Pharma US INC | $82.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $74.35 | 2019-2021 | |
| Abiomed | $38.69 | 2025 | |
| Esperion Therapeutics, INC. | $29.70 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $28.87 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28.78 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.14 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.10 | 2025 | |
| Irhythm Technologies, INC. | $22.94 | 2020 | |
| Inari Medical, INC. | $20.13 | 2022 | |
| Potrero Medical, INC. | $17.12 | 2023 | |
| Heartflow, INC. | $15.17 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.95 | 2024 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $13.49 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $13.27 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $3.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Hanfling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.